Mr Zhou was a partner and managing director of Eos Funds, where he directed investments in Chinese companies which intended to list on US and Canadian exchanges.
Mr Zhou was a postdotoral fellow in molecular biology at the University of Victoria, Canada and received a PhD in molecular biology from Umea University, Sweden. Mr Zhou had his master degree in genetics at Southwest University, China.
Charles Wan, CEO of Benda, said: “On behalf of the board of directors and management team, we welcome Mr George Zhou and look forward to his contributions. He has many years of experience as an entrepreneur and leader in China’s pharmaceutical industry, as well as experience as an investor in China. This makes him a superb fit for us, as we continue to grow our business and expand our presence throughout China and beyond.”